Updated Results of a Phase 1b/2 Study of Surufatinib Plus Camrelizumab, Nab-Paclitaxel and S-1 (NASCA) As First-Line Therapy for Metastatic Pancreatic Adenocarcinoma (Mpdac).
Journal of Clinical Oncology（2024）
关键词
283-2494,283-237-2581-242,3282-3301-4686-3729-3519-4685-2424,261-492-199-2823-5450,261-492-2769,613-135-244-3829,3282-3301-4686-3729-3519-4685-2805,4062,219,2950,4062,219,3618,2950,38092-23304,38092-20111,38092-27449,38092-20125,38092-20072,38092-20047
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要